Cagrisema
Aliases: cagrilintide + semaglutide · NN9838 + NN9534
Cagrisema is a cyclic peptide targeting GLP-1R, Amylin receptor, developed by Novo Nordisk for multiple indications. As of Aug 15, 2024, its highest verified stage is Phase 3.
Phase 3· verified Aug 15, 2024
Identity
- Generic name
- —
- Brand names
- —
- Development codes
- NN9838, NN9534
- Sponsor / originator
- Novo Nordisk
- Targets
- GLP-1RAmylin receptor
- Route / formulation
- Subcutaneous co-formulated injection
Development timeline
- Phase 3· Obesity· Global
As of Aug 15, 2024 · Confidence: high
Source: REDEFINE 1: Cagrisema for weight management in adults with overweight or obesityREDEFINE phase 3 program evaluating cagrisema vs comparators.
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| NCT05929066 | Phase 3 | Active, not recruiting | 3000 | Dec 1, 2025 |
Next catalysts
View all →Sources
- registryprimary record
REDEFINE 1: Cagrisema for weight management in adults with overweight or obesity
Novo Nordisk A/S · ClinicalTrials.gov · Jul 13, 2023 · NCT05929066